Most Recent

image: Freezing Time

Freezing Time

By | May 1, 2012

Targeting the briefest moment in chemistry may lead to an exceptionally strong new class of drugs.

15 Comments

image: New Target for Aspirin

New Target for Aspirin

By | April 20, 2012

New work on salicylate, a natural component of aspirin, suggests that activation of the energy-sensing AMP kinase may underlie some of aspirin’s health benefits.

6 Comments

image: An Antidote for Cocaine Overdose?

An Antidote for Cocaine Overdose?

By | April 19, 2012

A novel antibody with a powerful affinity for cocaine shows promise in reversing the deadly effects of an overdose.

2 Comments

image: Repurpose Failed Drugs, NIH Urges

Repurpose Failed Drugs, NIH Urges

By | April 16, 2012

Francis Collins says pharmaceutical companies should help bridge the gap between basic science and applications with old drug compounds.

0 Comments

image: Size Matters to Industry

Size Matters to Industry

By | April 11, 2012

Large molecules are more likely to make it to market these days than small molecules, according to new reports.

0 Comments

image: Obesity Drugs in Check

Obesity Drugs in Check

By | April 2, 2012

The FDA may require weight-loss drugs to undergo clinical trials to see if they pose a risk of heart attack.

2 Comments

image: The Two Faces of Metastasis

The Two Faces of Metastasis

By | April 1, 2012

During development, the cells of an embryo change their pattern of gene expression, which allows them to detach from their original location and migrate to another part of the embryo, where the pattern changes again to allow formation of a new organ.

0 Comments

image: Are Cancer Stem Cells Ready for Prime Time?

Are Cancer Stem Cells Ready for Prime Time?

By | April 1, 2012

A flood of new discoveries has refined our definition of cancer stem cells. Now it’s up to human clinical trials to test if they can make a difference in patients.

48 Comments

image: Failed Drugs Expose Preclinical Blunders

Failed Drugs Expose Preclinical Blunders

By | March 30, 2012

Once a promising cancer treatment, the failure of PARP inhibitors in the clinic may be due to flawed preclinical studies.

2 Comments

image: Collecting Cancer Data

Collecting Cancer Data

By | March 29, 2012

Two new cancer cell line databases bursting with genomic and drug profiling data may help researchers identify drug targets.

0 Comments

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Biology Research
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Diagenode Inc
Diagenode Inc